Edition:
United States

Trillium Therapeutics Inc (TRIL.OQ)

TRIL.OQ on NASDAQ Stock Exchange Capital Market

5.10USD
17 Aug 2018
Change (% chg)

$-0.05 (-0.97%)
Prev Close
$5.15
Open
$5.15
Day's High
$5.15
Day's Low
$5.05
Volume
3,700
Avg. Vol
12,575
52-wk High
$13.30
52-wk Low
$4.25

Latest Key Developments (Source: Significant Developments)

Trillium Therapeutics Inc Files For Mixed Shelf Of Upto $150 Mln
Friday, 15 Dec 2017 02:43pm EST 

Dec 15 (Reuters) - Trillium Therapeutics Inc ::TRILLIUM THERAPEUTICS INC FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING.  Full Article

Matrix Capital Management Co Reports A 16.5 Pct Passive Stake In Trillium Therapeutics
Friday, 8 Dec 2017 01:57pm EST 

Dec 8 (Reuters) - Trillium Therapeutics Inc ::MATRIX CAPITAL MANAGEMENT COMPANY LP REPORTS A 16.5 PCT PASSIVE STAKE IN TRILLIUM THERAPEUTICS INC <<>> AS OF NOV 30 - SEC FILING.  Full Article

Trillium announces private placement to fund development of cancer drugs
Wednesday, 15 Nov 2017 09:15am EST 

Nov 15 (Reuters) - Trillium Therapeutics Inc -:Trillium announces private placement.Trillium Therapeutics - ‍entered into subscription agreements for sale of 1.95 million shares & 400,000 Series II non-voting convertible first preferred shares​.Trillium Therapeutics - ‍net proceeds from private placement will be used to continue development of TTI-621 in hematologic cancers and solid tumors​.Trillium Therapeutics Inc - ‍subscription agreements for offering at a price of U.S.$8.50 per share.  Full Article

Trillium Therapeutics reports Q3 results
Friday, 10 Nov 2017 07:00am EST 

Nov 10 (Reuters) - Trillium Therapeutics Inc :Trillium Therapeutics reports third quarter 2017 financial and operating results.Trillium Therapeutics Inc - ‍Cash and marketable securities of $64.3 million at September 30, 2017​.  Full Article

Trillium expands clinical trial with TTI-621
Wednesday, 7 Jun 2017 07:00am EDT 

June 7 (Reuters) - Trillium Therapeutics Inc :Trillium expands clinical trial with tti-621 to include combination with pd-1 blockade.Trillium therapeutics inc - ‍further expanded its current intravenous dosing trial of tti-621, an igg1 sirpafc fusion protein targeting cd47​.Trillium therapeutics inc - ‍changes to trial include increasing size of cohorts exhibiting early evidence of clinical benefit, among others​.  Full Article

Cormorant Asset Management reports 5.66 pct passive stake in Trillium Therapeutics
Monday, 5 Jun 2017 04:30pm EDT 

June 5 (Reuters) - Trillium Therapeutics Inc ::Cormorant Asset Management Llc reports 5.66 percent passive stake in Trillium Therapeutics Inc as of may 26 - sec filing.  Full Article

Trillium announces pricing of U.S.$30.0 mln public offering of common shares
Friday, 26 May 2017 08:30am EDT 

May 26 (Reuters) - Trillium Therapeutics Inc : :Trillium announces pricing of U.S.$30.0 million public offering of common shares and series II non-voting convertible first preference shares.Trillium Therapeutics Inc - priced its public offering of 2.8 million common shares and 3.3 million series II non-voting convertible first preferred shares.Trillium Therapeutics Inc - common shares are being sold at a public offering price of U.S.$5.00 per share.Trillium Therapeutics Inc - series II non-voting convertible first preferred shares are being sold at a public offering price of U.S.$5.00 per share.  Full Article

Trillium Therapeutics offers shares in public offering
Thursday, 25 May 2017 04:01pm EDT 

May 25 (Reuters) - Trillium Therapeutics Inc :Trillium announces proposed public offering.Trillium therapeutics inc - intends to use net proceeds of offering to advance and expand current phase 1 trial of sirpαfc.Trillium therapeutics - to use net proceeds to initiate , conduct a phase 1 trial for tti-622 with dose escalation and expansion phase focused on combination treatment.  Full Article

Trillium reports qtrly basic and diluted loss per common share $1.46
Friday, 12 May 2017 07:00am EDT 

May 12 (Reuters) - Trillium Therapeutics Inc : :Trillium reports first quarter 2017 financial and operating results.Qtrly basic and diluted loss per common share $1.46.Trillium Therapeutics- net loss for three months ended March 31, 2017 of $11.5 million was higher than loss of $7.2 million for three months ended March 31, 2016.Qtrly net loss was higher due mainly to increased research and development program expenses of $2.8 million.All figures in C$.  Full Article

Trillium Therapeutics says TTI-621 program momentum continues in 2017
Friday, 10 Mar 2017 07:00am EST 

Trillium Therapeutics Inc : Trillium reports annual 2016 financial and operating results .Trillium therapeutics inc - "tti-621 program momentum continues in 2017".  Full Article

BRIEF-Trillium Therapeutics Files Prospectus Related To Offering Of 2.35 Mln Co's Common Shares By Selling Shareholders

* TRILLIUM THERAPEUTICS INC FILES PROSPECTUS RELATED TO OFFERING OF 2.35 MILLION CO'S COMMON SHARES BY SELLING SHAREHOLDERS - SEC FILING Source text: (https://bit.ly/2IoCJmp) Further company coverage: